It has been confirmed that renal lipid deposition is accelerated under the inhibition of Nrf2 in obesity-associated kidney damage [17], whereas Nrf2 activators effectively ameliorate oxidative stress and inflammation in animal models of kidney disease [18]. The gene discussed is NFE2L2; the disease is Nephropathy.